PL378291A1 - Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin - Google Patents

Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin

Info

Publication number
PL378291A1
PL378291A1 PL378291A PL37829104A PL378291A1 PL 378291 A1 PL378291 A1 PL 378291A1 PL 378291 A PL378291 A PL 378291A PL 37829104 A PL37829104 A PL 37829104A PL 378291 A1 PL378291 A1 PL 378291A1
Authority
PL
Poland
Prior art keywords
cells
csf
dendritic
monocytes
dendritic cells
Prior art date
Application number
PL378291A
Other languages
English (en)
Other versions
PL209998B1 (pl
Inventor
Benjamin A. Tjoa
Marnix L. Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of PL378291A1 publication Critical patent/PL378291A1/pl
Publication of PL209998B1 publication Critical patent/PL209998B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL378291A 2003-02-27 2004-02-27 Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne PL209998B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27
PCT/US2004/006119 WO2004076651A2 (en) 2003-02-27 2004-02-27 Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines

Publications (2)

Publication Number Publication Date
PL378291A1 true PL378291A1 (pl) 2006-03-20
PL209998B1 PL209998B1 (pl) 2011-11-30

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378291A PL209998B1 (pl) 2003-02-27 2004-02-27 Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne

Country Status (20)

Country Link
US (4) US8389278B2 (pl)
EP (1) EP1604016B1 (pl)
JP (1) JP4762887B2 (pl)
KR (2) KR20110106474A (pl)
CN (1) CN1784488B (pl)
AT (1) ATE420946T1 (pl)
AU (2) AU2004214896A1 (pl)
BR (1) BRPI0407900A (pl)
CA (1) CA2517295C (pl)
CY (1) CY1109099T1 (pl)
DE (1) DE602004019057D1 (pl)
DK (1) DK1604016T3 (pl)
ES (1) ES2321939T3 (pl)
IL (1) IL170512A (pl)
MX (1) MXPA05009178A (pl)
NZ (1) NZ542071A (pl)
PL (1) PL209998B1 (pl)
RU (1) RU2364625C2 (pl)
TW (1) TW200506061A (pl)
WO (1) WO2004076651A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
EP2260861A1 (en) * 2002-12-06 2010-12-15 NorthWest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
US7939090B2 (en) * 2003-10-21 2011-05-10 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
US7790039B2 (en) 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
KR20150032915A (ko) 2005-04-08 2015-03-30 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
CA2632263C (en) * 2005-12-08 2022-01-11 Northwest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
EP1806395A1 (en) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP1920782A1 (en) * 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
WO2009155332A1 (en) * 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
PL2328923T3 (pl) * 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
ES2618573T3 (es) 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd Epítopos de CD133
ES2711504T3 (es) * 2009-07-24 2019-05-06 Rhode Island Hospital Vacunas de células dendríticas para tumores que expresan asparaginil-beta-hidroxilasa
AU2010307075B2 (en) 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
RU2575978C2 (ru) * 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
JP5577472B2 (ja) * 2012-02-10 2014-08-20 医療法人社団博心厚生会 単球増殖剤、単球増殖用培地、単球の製造方法、樹状細胞の製造方法、及び樹状細胞ワクチンの製造方法
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2016011878A1 (zh) * 2014-07-23 2016-01-28 国家纳米科学中心 一种抑制肿瘤转移和治疗白血病的多肽和多肽复合物、其制备方法及其应用
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
JP6985939B2 (ja) * 2015-06-30 2021-12-22 ノースウエスト バイオセラピューティクス，インコーポレイティド 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞
EP3350318B1 (en) 2015-09-15 2022-04-13 NorthWest Biotherapeutics, Inc. Methods relating to activated dendritic cell compositions for subjects with advanced cancers
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
US12239666B2 (en) 2018-06-19 2025-03-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
IL286907B2 (en) * 2019-04-03 2025-11-01 Akron Bioproducts Llc Cryopreservation and cell culture media
WO2021010344A1 (ja) * 2019-07-12 2021-01-21 国立大学法人九州大学 心筋収縮改善治療法および心筋細胞死抑制法の開発
BR112022009560A2 (pt) * 2019-11-18 2022-08-02 Childrens Medical Center Células dendríticas hiperativas possibilitam imunidade antitumoral baseada na transferência de células adotivas duráveis
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
US20240207308A1 (en) * 2021-05-07 2024-06-27 NANOFAENTECH CO., Ltd. Method for culturing dendritic cells
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US20230227780A1 (en) * 2022-01-20 2023-07-20 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
US12584107B2 (en) * 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
CN118389430A (zh) * 2024-04-12 2024-07-26 广东壹加再生医学研究院有限公司 一种高抗肿瘤特异性dc-cik细胞的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683956D1 (de) * 1985-06-11 1992-04-02 Us Commerce In einem serumfreien medium in suspension kultivierte humane monozyten.
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
EP2322603B1 (en) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response
AU2003243673B2 (en) * 2002-06-19 2010-01-21 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for leukocyte enrichment
CN1761744A (zh) * 2003-02-10 2006-04-19 西北生物治疗药物公司 培养的cd14+抗原呈递细胞

Also Published As

Publication number Publication date
JP4762887B2 (ja) 2011-08-31
ES2321939T3 (es) 2009-06-15
US20040203143A1 (en) 2004-10-14
US20210102169A1 (en) 2021-04-08
EP1604016B1 (en) 2009-01-14
CA2517295A1 (en) 2004-09-10
CN1784488B (zh) 2010-07-28
NZ542071A (en) 2007-11-30
US20130273654A1 (en) 2013-10-17
AU2004214896A1 (en) 2004-09-10
KR20050107471A (ko) 2005-11-11
DK1604016T3 (da) 2009-05-18
RU2005129561A (ru) 2006-03-10
US11827903B2 (en) 2023-11-28
KR101201875B1 (ko) 2012-11-15
HK1086597A1 (en) 2006-09-22
ATE420946T1 (de) 2009-01-15
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
US9102917B2 (en) 2015-08-11
IL170512A (en) 2013-12-31
TW200506061A (en) 2005-02-16
EP1604016A4 (en) 2006-03-08
CY1109099T1 (el) 2014-07-02
KR20110106474A (ko) 2011-09-28
JP2006519021A (ja) 2006-08-24
DE602004019057D1 (de) 2009-03-05
BRPI0407900A (pt) 2006-03-21
WO2004076651A3 (en) 2005-03-10
EP1604016A2 (en) 2005-12-14
RU2364625C2 (ru) 2009-08-20
US8389278B2 (en) 2013-03-05
WO2004076651A2 (en) 2004-09-10
AU2010201319A1 (en) 2010-04-29
CN1784488A (zh) 2006-06-07
AU2010201319B2 (en) 2012-09-06
US10731130B2 (en) 2020-08-04
PL209998B1 (pl) 2011-11-30
CA2517295C (en) 2016-01-12

Similar Documents

Publication Publication Date Title
MXPA05009178A (es) Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citocinas adicionales.
Li et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway
Romani et al. Proliferating dendritic cell progenitors in human blood.
Santini et al. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity
Khosravi et al. Induction of CD4+ CD25+ FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation
Chaperot et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts
WO2006065495A3 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
EP2722387A3 (en) Definitive endoderm
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
WO2003083089A3 (en) Tolerogenic antigen-presenting cells
Jegatheeswaran et al. Searching for the elusive regulatory innate lymphoid cell
Holtick et al. Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells
Dahlqvist et al. Modulatory effect of rapamycin and tacrolimus on monocyte-derived dendritic cells phenotype and function
NZ587598A (en) Methods of increasing proliferation of a cell by administering a low magnitude, high frequency mechanical signal
AU2001259744A1 (en) Compositions and methods for producing antigen-presenting cells
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
EP2484759A3 (en) Methods of refolding mammalian glycosyltransferases
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity
CA2510596A1 (en) Dendritic cell line
EP2377922A3 (en) PDX1 expressing endoderm
WO2005023982A3 (en) Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients
AU8478601A (en) Methods for culturing human lung mast cells and uses thereof
MX2007005928A (es) Metodos para la produccion de celulas de mamiferos.
EP1927657A3 (en) Compositions and methods for producing antigen-presenting cells
CA2442300A1 (en) Cd8.alpha. + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation